These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11228207)

  • 1. Effect of feeding on growth hormone response to growth hormone-releasing hormone in polycystic ovarian syndrome: relation with body weight and hyperinsulinism.
    Villa P; Soranna L; Mancini A; De Marinis L; Valle D; Mancuso S; Lanzone A
    Hum Reprod; 2001 Mar; 16(3):430-4. PubMed ID: 11228207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia.
    Lanzone A; Villa P; Fulghesu AM; Pavone V; Caruso A; Mancuso S
    Hum Reprod; 1995 Jul; 10(7):1653-7. PubMed ID: 8582956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism.
    Villa P; Valle D; Mancini A; De Marinis L; Pavone V; Fulghesu AM; Mancuso S; Lanzone A
    Fertil Steril; 1999 Jan; 71(1):115-21. PubMed ID: 9935127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the opioid blockade on the feeding-induced growth hormone response to growth hormone-releasing hormone in women with polycystic ovary syndrome.
    Guido M; Romualdi D; Mancini A; Lattanzi F; Villa P; Barini A; Lanzone A; De Marinis L
    Fertil Steril; 2002 Nov; 78(5):994-1000. PubMed ID: 12413983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of long-term naltrexone treatment on growth hormone and insulin secretion in hyperandrogenic and normal obese patients.
    Villa P; Fulghesu AM; De Marinis L; Valle D; Mancini A; Pavone V; Caruso A; Lanzone A
    Metabolism; 1997 May; 46(5):538-43. PubMed ID: 9160821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth-hormone response to combined stimulation with GHRH plus GH-releasing peptide-6 in obese patients with polycystic ovary syndrome before and after short-term fasting.
    Micić D; Sumarac-Dumanović M; Macut Dj; Kendereski A; Zoric S; Popović V; Cvijović G; Dieguez C; Casanueva FF
    J Endocrinol Invest; 2003 Apr; 26(4):333-40. PubMed ID: 12841541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome.
    Guido M; Romualdi D; Giuliani M; Suriano R; Tienforti D; Costantini B; Lanzone A
    Fertil Steril; 2005 Nov; 84(5):1470-6. PubMed ID: 16275246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.
    Orio F; Palomba S; Colao A; Russo T; Dentico C; Tauchmanovà L; Savastano S; Nappi C; Sultan C; Zullo F; Lombardi G
    J Endocrinol Invest; 2003 Feb; 26(2):117-22. PubMed ID: 12739737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
    Lanzi R; Luzi L; Caumo A; Andreotti AC; Manzoni MF; Malighetti ME; Sereni LP; Pontiroli AE
    Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid dysregulation after biliopancreatic diversion: effect of naloxone on preprandial and postprandial growth hormone (GH)-releasing hormone-induced GH release in surgically induced weight loss.
    Mancini A; Bianchi A; Tacchino RM; Perrelli M; Milardi D; Gentilella R; Giampietro A; Fusco A; Valle D; De Marinis L
    Metabolism; 2001 Apr; 50(4):382-6. PubMed ID: 11288030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
    Ciampelli M; Muzj G; Leoni F; Romualdi D; Belosi C; Cento RM; Lanzone A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5324-9. PubMed ID: 11701699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of pre- and postprandial growth hormone (GH)-releasing hormone-induced GH response in subjects with persistent body weight normalisation after biliopancreatic diversion.
    De Marinis L; Mancini A; Valle D; Tacchino RM; Bianchi A; Gentilella R; Perrelli M; Castagneto M; Gasbarrini G
    Int J Obes Relat Metab Disord; 1998 Oct; 22(10):1011-8. PubMed ID: 9806317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects.
    De Marinis L; Mancini A; Valle D; Izzi D; Bianchi A; Gentilella R; Giampietro A; Desenzani P; Giustina A
    Horm Metab Res; 2000 Apr; 32(4):152-6. PubMed ID: 10824712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfunction of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovarian syndrome.
    Piaditis GP; Kounadi TG; Rangou DB; Trovas GP; Kaklas NA; Tzonou AJ; Chlouverakis CS
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):635-40. PubMed ID: 7634505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GH response to GHRH before and after meals at different hours of the day in obese patients.
    De Marinis L; Mancini A; Zuppi P; D'Amico C; Fiumara C; Calabro F; Lagonigro G; La Brocca A
    Psychoneuroendocrinology; 1991; 16(4):361-5. PubMed ID: 1745702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of protein ingestion on GH concentrations in visceral obesity.
    van Vught AJ; Nieuwenhuizen AG; Veldhorst MA; Brummer RJ; Westerterp-Plantenga MS
    Horm Metab Res; 2010 Sep; 42(10):740-5. PubMed ID: 20582874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
    Alvarez-Castro P; Isidro ML; Garcia-Buela J; Leal-Cerro A; Broglio F; Tassone F; Ghigo E; Dieguez C; Casanueva FF; Cordido F
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.